Last reviewed · How we verify
NCT05624333: VD2O
Vegan Diets: the Short-term Effects on Daily Muscle Protein Synthesis Rates as Compared to Omnivorous Diets in Older Adults Assessed by D2O.
NA trial testing Vegan diet (intervention) in Sarcopenia in 38 participants. Completed in 13 February 2023.
13 February 2023
Quick facts
| Lead sponsor | Wageningen University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 38 |
| Start date | 9 January 2023 |
| Primary completion | 13 February 2023 |
| Estimated completion | 13 February 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Vegan diet (intervention)
- Omnivorous diet (control)
Conditions studied
- Sarcopenia — all drugs for Sarcopenia →
Sponsor
Wageningen University
Who can join
Adults 65 to 79, any sex, with Sarcopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Consumers are increasingly encouraged to consume more plant-based foods and lower their consumption of foods from animal origin. However, the consequences of such a transition on muscle mass still remains to be explored. This is of particular importance in the older population, where sarcopenia is highly prevalent. The aim of this randomized controlled cross-over study is to investigate the short-term effect of a 10-day controlled vegan diet on daily muscle fractional synthesis rates in comparison to a 10-day controlled omnivorous diet in 35 community-dwelling older adults. Participants will follow a fully controlled vegan diet, directly followed by a fully controlled omnivorous diet for 10 days, or vice versa. Researchers will compare the effect of the vegan diet to the effect of the omnivorous diet.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Well-Balanced Vegan Diet Does not Compromise Daily Mixed Muscle Protein Synthesis Rates when Compared with an Omnivorous Diet in Active Older Adults: A Randomized Controlled Cross-Over Trial.
Domić J, Pinckaers PJ, Grootswagers P, Siebelink E, et al · · 2025 · cited 9× · PMID 39732437 · DOI 10.1016/j.tjnut.2024.12.019
Verify or expand the search:
- PubMed search for NCT05624333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcopenia
Currently open trials in the same condition.
- NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting
Other Wageningen University trials
Trials by the same sponsor.
- NCT07361406 — SweetSpot - The Effect of Non-nutritive Sweeteners on Health · NA · recruiting
- NCT07421466 — Umami Taste Intensity and Meal Intake · NA · completed
- NCT07075991 — Uptake and Excretion of a Single Dose of Oral 14C-labelled Polystyrene Microplastics in Healthy Volunteers · NA · completed
- NCT07059117 — Umami Taste Intensity and ad Libitum Meal Intake · NA · completed
- NCT06750497 — Forearm Immobilization in T2D · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05624333 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wageningen University
- Last refreshed: 24 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05624333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing